Amicus Therapeutics stock trades at USD 8.42 as Fabry focus persists

Amicus Therapeutics stock (ISIN US03152W1099) traded at USD 8.42 on Nasdaq on September 23, 2026, giving the company a market capitalization of USD 1.31 billion. The valuation remains tied to the commercial performance of its Fabry disease medicines, particularly Galafold.

Fabry treatment remains central

Amicus Therapeutics markets Galafold, also known as migalastat, for Fabry disease, a rare inherited disorder. A September 23, 2026 market overview identified migalastat as an Amicus product within the Fabry disease treatment landscape, linking the company to a market expected to expand through 2036.

The commercial argument is concentrated rather than broad. Galafold is the company's principal named product in the current sector material, so revenue execution, patient uptake and competitive positioning remain important operating variables for the shares.

Market value sets the reference

The September 23, 2026 Nasdaq quotation of USD 8.42 supplies the reference price, while the USD 1.31 billion market capitalization places Amicus in the small-cap biotechnology segment. The stock therefore combines a clearly measurable equity value with exposure to a specialized rare-disease market.

The current comparison is between the company's USD 1.31 billion equity value and the long-dated Fabry market opportunity extending to 2036. That comparison does not establish a valuation conclusion, but it shows why product adoption and commercial execution matter more than broad pharmaceutical averages for this stock.

Stock stays linked to execution

Amicus Therapeutics stock closed at USD 8.42 on Nasdaq on September 23, 2026. The dated price and market capitalization provide the market baseline, while Galafold and the Fabry disease market remain the clearest operating reference points in the available current coverage.

More news and analyses on Amicus Therapeutics stock